{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/sickle-cell-disease/management/management-chronic-complications/","result":{"pageContext":{"chapter":{"id":"2bf8553c-1641-5bdc-bbc3-2615ddc5b84c","slug":"management-chronic-complications","fullItemName":"Scenario: Management - chronic complications","depth":2,"htmlHeader":"<!-- begin field 9f3e1d2f-af83-42fa-b33c-f337b24c9f63 --><h2>Scenario: Management - chronic complications</h2><!-- end field 9f3e1d2f-af83-42fa-b33c-f337b24c9f63 -->","summary":"Covers the management of chronic complications of sickle cell disease in primary care.","htmlStringContent":"<!-- begin item b3f209d0-e7ec-4e7e-a8e2-4e0198fd02fe --><!-- begin field fb0c1332-2bab-4b86-b84d-acbd00886134 --><p>From birth onwards.</p><!-- end field fb0c1332-2bab-4b86-b84d-acbd00886134 --><!-- end item b3f209d0-e7ec-4e7e-a8e2-4e0198fd02fe -->","topic":{"id":"eb346bd0-1df2-5db2-a583-a366e34cfc19","topicId":"cc107f5d-efe6-4625-840e-5c4d4656869b","topicName":"Sickle cell disease","slug":"sickle-cell-disease","lastRevised":"Last revised in November 2016","chapters":[{"id":"d2b6d668-4d29-5c50-b65d-7467cbcce2dd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47f9af8d-8bda-55a3-bf81-eb75a7c4f02a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4a0ece3e-fa44-5ecd-9f55-ac17384d960c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"44a5b5f9-fc8e-5024-87e3-a7e42dca3dd9","slug":"changes","fullItemName":"Changes"},{"id":"48757ec5-731a-57fd-8e39-d2cdf918179a","slug":"update","fullItemName":"Update"}]},{"id":"53ae2089-f545-5b24-99c5-a9fc620ea575","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ffff20e4-5bc5-5c3b-bb59-858dba2fcf8d","slug":"goals","fullItemName":"Goals"},{"id":"16f85d1d-aec7-5173-9e0b-7d9456bdf3a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12a41d5f-f447-5a64-868a-7648c7de9355","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5de2a0f3-a77d-5244-a401-dbd2cbcfefb3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fc893fb4-51ec-5705-8dff-c7fba1969646","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cc1cc5c4-df13-5e74-bde0-9f625ec4d1cf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"02e2bd4f-75cd-5b59-9a81-c06d3bcf4d2f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2a8eb5f7-6691-505b-bd86-9620102057a3","slug":"definition","fullItemName":"Definition"},{"id":"b756c83a-dcc0-5792-b3f9-fa9416929ce3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"488c0ab1-f1c0-5fbf-bd1e-e327181c2e1f","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b62a5aae-0dc3-5ac0-a1b1-d3ca0a7969ac","slug":"complications","fullItemName":"Complications"}]},{"id":"9336c0e7-d5d3-5dd6-99fd-50610ced96e1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dd5a2bec-36ce-58c0-b0f1-4ec5d4d17c21","slug":"when-to-suspect-sickle-cell-disease","fullItemName":"When to suspect sickle cell disease"},{"id":"bdbf4e2a-7a0c-5a2e-8b9c-4a9c661409ef","slug":"diagnosis-of-sickle-cell-disease","fullItemName":"Diagnosis of sickle cell disease"},{"id":"68746f0d-607a-5db5-8949-a87a4ed29328","slug":"when-to-suspect-an-acute-sickle-cell-crisis","fullItemName":"When to suspect an acute sickle cell crisis"},{"id":"ed48dbda-a404-50cf-a290-86fafcdb9908","slug":"assessment-of-acute-crisis","fullItemName":"Assessment of acute crisis"}]},{"id":"221fb88b-b951-5835-b282-ed218b637ff0","fullItemName":"Management","slug":"management","subChapters":[{"id":"e76854fe-5d45-5d85-8591-5712daa7e4d9","slug":"screening","fullItemName":"Scenario: Screening"},{"id":"1da4d393-99a4-51c1-b354-f1742b9d8b1f","slug":"management-sickle-cell-crisis","fullItemName":"Scenario: Management - sickle cell crisis"},{"id":"2bf8553c-1641-5bdc-bbc3-2615ddc5b84c","slug":"management-chronic-complications","fullItemName":"Scenario: Management - chronic complications"},{"id":"4493185d-8907-5325-a195-a7cd7039bd68","slug":"prevention-of-complications","fullItemName":"Scenario: Prevention of complications"},{"id":"2aeac855-0e31-598c-804d-41c8d9bc643f","slug":"management-sickle-cell-trait","fullItemName":"Scenario: Management - sickle cell trait"},{"id":"5b85ac92-9286-564f-88fb-ec37a6f4102e","slug":"contraception","fullItemName":"Scenario: Contraception"}]},{"id":"a424bf70-c56c-54a4-a2e2-019ab7c27c69","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"515607d5-c2e2-5a4c-8d83-1bb5e320badf","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2148be5b-6502-5e45-b86b-e552aa3226fd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"acc3b704-7f3d-51ed-869e-38e0309c53e5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a46384b-d43c-536a-9a17-4b8953d8457a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"46873f42-ab32-5894-b2fe-429a4e62161b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1dd24310-b8ac-5381-b51a-ca1f6c178d72","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7405fe0a-8432-5e64-9fe0-4d112fd89232","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"221fb88b-b951-5835-b282-ed218b637ff0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"85493bc2-67c3-54b0-b659-fd50b531c218","slug":"overview-of-management","fullItemName":"Overview of management","depth":3,"htmlHeader":"<!-- begin field 239fcb2c-6c52-4309-a25e-39fa8df4ee36 --><h3>Overview of management</h3><!-- end field 239fcb2c-6c52-4309-a25e-39fa8df4ee36 -->","summary":null,"htmlStringContent":"<!-- begin item 803643f4-fdc2-4f1c-a0a4-60cba595ab15 --><!-- begin field 08d48e36-10c7-4f2a-9fe1-92ff77ef2827 --><p><strong>The management of chronic complications of sickle cell disease needs a multidisciplinary approach. Children and adults are seen regularly in secondary care. However, it is recommended that as much of the management as possible should take place in the community.</strong></p><ul><li><strong>Primary care clinicians should:</strong><ul><li>Admit or refer people immediately if they have new symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-cerebrovascular-disease\">cerebrovascular disease</a>, as acute strokes are devastating in both children and adults.</li><li>Manage <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-chronic-pain\">chronic pain</a> with care.</li><li>Treat chest infections early, especially in people with <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-chronic-sickle-lung\">chronic sickle lung</a>.</li><li>Refer people with <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-eye-problems\">eye problems</a> urgently. </li><li>Refer people for consideration for cholecystectomy if they have symptomatic <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-gallstones\">gallstones</a>.</li><li>Address concerns about <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-impaired-growth\">impaired growth</a> or delayed puberty.</li><li>Manage <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-leg-ulcers\">leg ulcers</a> appropriately.</li><li>Refer people with suspected <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-pulmonary-hypertension\">pulmonary hypertension</a>, or worsening symptoms.</li><li>Manage <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-episodes-of-priapism\">minor episodes of priapism</a>. It is important to enquire about this issue as the person may be too embarrassed to report it.</li><li>Manage <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-nocturnal-enuresis\">nocturnal enuresis</a>, which is common because of the production of large quantities of dilute urine.</li><li>Identify <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-renal-disease-hypertension\">renal problems</a> early, and treat hypertension aggressively.</li><li>Refer people with <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/management-chronic-complications/#managing-sleep-apnoea\">sleep apnoea</a>.</li><li>Advice on <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/prevention-of-complications/\">measures</a> to prevent (or reduce the risk of) complications.</li></ul></li></ul><!-- end field 08d48e36-10c7-4f2a-9fe1-92ff77ef2827 --><!-- end item 803643f4-fdc2-4f1c-a0a4-60cba595ab15 -->","subChapters":[{"id":"4da13b8d-55b3-55e5-97d2-6a4fd79937e8","slug":"managing-cerebrovascular-disease","fullItemName":"Managing cerebrovascular disease","depth":4,"htmlHeader":"<!-- begin field d45f9e09-9ed9-4cc8-9c28-2e5ce75bccc9 --><h4>How should I manage cerebrovascular disease in a person with sickle cell disease?</h4><!-- end field d45f9e09-9ed9-4cc8-9c28-2e5ce75bccc9 -->","summary":null,"htmlStringContent":"<!-- begin item 8ed22157-85a3-4b93-9c09-9d359153a052 --><!-- begin field b5939b06-48f0-4efd-ab53-c82c6df6e948 --><p><strong>People who have had a stroke will be managed in secondary care with regular follow up. </strong><strong>Most people will have regular blood transfusions (preferably exchange transfusions) to keep their sickle haemoglobin percentage below 30% indefinitely. This means that people are also monitored for iron overload. All children should have annual transcranial Doppler imaging from 3 years of age.</strong></p><ul><li><strong>Be alert for new symptoms of cerebrovascular disease.</strong><ul><li><strong>Admit all children and adults for urgent assessment if they present with:</strong><ul><li>A history suggestive of transient ischaemic attacks.</li><li>A first episode of an acute severe headache, or a significant change in the type of headache, as these may be presenting features of intracranial haemorrhage or venous sinus thrombosis.</li></ul></li><li><strong>Refer all children and adults for urgent assessment if they present with:</strong><ul><li>Cognitive abnormalities, as these may be due to silent infarcts. There may be a decline in academic performance, which always justifies investigation.</li></ul></li></ul></li></ul><!-- end field b5939b06-48f0-4efd-ab53-c82c6df6e948 --><!-- end item 8ed22157-85a3-4b93-9c09-9d359153a052 -->","subChapters":[{"id":"44143bd0-4b38-5dcf-bb58-3d3b83be3294","slug":"basis-for-recommendation-066","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 1038c22f-f33b-4c4f-bd40-0dd60c235ac6 --><h5>Basis for recommendation</h5><!-- end field 1038c22f-f33b-4c4f-bd40-0dd60c235ac6 -->","summary":null,"htmlStringContent":"<!-- begin item 0663e90e-a711-4fd3-9811-76c41404f4f7 --><!-- begin field 15c4b5f2-6856-4dfd-a250-67d81775aed9 --><p>These recommendations are largely based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</p><!-- end field 15c4b5f2-6856-4dfd-a250-67d81775aed9 --><!-- end item 0663e90e-a711-4fd3-9811-76c41404f4f7 -->","subChapters":[]}]},{"id":"46cdc11e-5f78-5d2a-9ded-2fc589d087ea","slug":"managing-chronic-pain","fullItemName":"Managing chronic pain","depth":4,"htmlHeader":"<!-- begin field bb427c49-7c76-4c60-a8b4-c82c66a0d1d5 --><h4>How should I manage chronic pain in a person with sickle cell disease? </h4><!-- end field bb427c49-7c76-4c60-a8b4-c82c66a0d1d5 -->","summary":null,"htmlStringContent":"<!-- begin item 82b46deb-2f2e-412f-b4a5-3654bce04429 --><!-- begin field b112e265-341c-4dff-bf55-d680aa1c9fd5 --><p><strong>All types of chronic pain in sickle cell disease require multidisciplinary support, with the general approach being similar to other types of chronic pain. Although the person should be attending regular review by a specialist, most of the management of chronic pain will take place in primary care.</strong></p><ul><li><strong>Determine the <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/background-information/complications/#chronic-complications\">cause of pain</a>, if possible. </strong>Common causes include chronic arthritis, avascular necrosis, or vertebral collapse.</li><li><strong>Consider the need for referral.</strong><ul><li>Refer<strong> </strong>people with persistent pain to an orthopaedic surgeon for investigations, including magnetic resonance imaging (MRI).</li><li>Refer people with avascular necrosis for rapid assessment and operation if deemed necessary. The initial management should be conservative, with analgesia, physiotherapy, and partial weight-bearing on crutches.</li></ul></li><li><strong>If referral is not indicated, manage pain in primary care.</strong><ul><li>Explain that chronic pain is difficult to eradicate and that the aim is to relieve pain as much as possible.<ul><li>Prescribe regular medium- to long-acting opiates and monitor the person regularly. Prescribe an opiate for breakthrough pain. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> for prescribing information. </li><li>Consider a nonsteroidal anti-inflammatory drug (NSAID), provided there are no contraindications. Monitor renal function and proteinuria regularly if an NSAID is prescribed. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> for prescribing information. </li></ul></li><li>Neuropathic pain may also occur in people with sickle cell disease. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a> for more information. </li><li>Psychological therapies (for example relaxation, hypnosis, and cognitive behavioural therapy [CBT]) may be helpful for some people. <ul><li>CBT will be considered in secondary care for all children who have frequent episodes of pain </li></ul></li></ul></li><li><strong>Ensure that the person has an annual needs assessment, medication review, and health education.</strong><ul><li>This should be done wherever is most suitable for the person (that is, in primary, secondary, or community care) and should cover: <ul><li>Pain control and the person's expectations of pain control.</li><li>Career, vocational, and employment advice.</li><li>Occupational and/or psychological therapy.</li><li>Advice on minimizing harm, for example avoiding high-impact exercise or sports (as they can exacerbate damage) and maintaining a healthy weight.</li></ul></li><li>Where appropriate, involve family members, friends, and carers.</li></ul></li></ul><!-- end field b112e265-341c-4dff-bf55-d680aa1c9fd5 --><!-- end item 82b46deb-2f2e-412f-b4a5-3654bce04429 -->","subChapters":[{"id":"aacc83e7-6e4f-575b-bc15-9060acb75cb2","slug":"basis-for-recommendation-208","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 36c10043-c134-4115-ba41-742aa2a0ae95 --><h5>Basis for recommendation</h5><!-- end field 36c10043-c134-4115-ba41-742aa2a0ae95 -->","summary":null,"htmlStringContent":"<!-- begin item 2082e2a0-0ab4-4d88-a18c-b1ae00b6a672 --><!-- begin field 97df8af3-3726-4873-adaf-a10868cebe5e --><p>These recommendations are largely based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>], and in a review article on managing sickle cell disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Brousse et al, 2014</a>].</p><h6>Psychological therapies</h6><ul><li>The information on psychological therapies is also based on a Cochrane systematic review (search date: Januray 2014), which found evidence that psychological therapies may help children and adolescents manage pain and its disabling consequences [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Eccleston et al, 2014</a>].<ul><li>The evidence showed that both relaxation and cognitive behavioural therapy are effective in reducing the intensity of pain from different causes, including sickle cell disease (2 studies, n = 91), immediately after treatment.</li></ul></li></ul><!-- end field 97df8af3-3726-4873-adaf-a10868cebe5e --><!-- end item 2082e2a0-0ab4-4d88-a18c-b1ae00b6a672 -->","subChapters":[]}]},{"id":"8dfbaf06-038c-5473-bcc0-c861f4c7f1ea","slug":"managing-chronic-sickle-lung","fullItemName":"Managing chronic sickle lung","depth":4,"htmlHeader":"<!-- begin field 3de034a4-0b6b-4edb-a44d-a0c1decac25d --><h4>How should I manage chronic sickle lung in a person with sickle cell disease?</h4><!-- end field 3de034a4-0b6b-4edb-a44d-a0c1decac25d -->","summary":null,"htmlStringContent":"<!-- begin item 1b2e6b91-cabb-4d6e-b589-2f25211a6c3c --><!-- begin field 08927f04-b29c-4743-a0dc-14ecf601f465 --><p><strong>Children and adults with chronic sickle lung disease will be managed in secondary care. </strong></p><ul><li><strong>The primary care physician should:</strong><ul><li>Treat any chest infection early.</li><li>Give advice on smoking cessation, where necessary. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>Ensure vaccinations are up to date. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/sickle-cell-disease/management/prevention-of-complications/#recommended-immunizations\">Immunizations</a> for more information. </li></ul></li></ul><!-- end field 08927f04-b29c-4743-a0dc-14ecf601f465 --><!-- end item 1b2e6b91-cabb-4d6e-b589-2f25211a6c3c -->","subChapters":[{"id":"3601c681-eefa-5bf9-b79e-5527cb485889","slug":"basis-for-recommendation-fc0","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 6cabde1d-172a-4386-b3da-3aad797eb20c --><h5>Basis for recommendation</h5><!-- end field 6cabde1d-172a-4386-b3da-3aad797eb20c -->","summary":null,"htmlStringContent":"<!-- begin item fc011566-40d9-4bba-81bd-74870bb856ba --><!-- begin field b0d364ef-bde0-4cb5-8147-86a3a2a2b7f4 --><p>These recommendations are based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</p><!-- end field b0d364ef-bde0-4cb5-8147-86a3a2a2b7f4 --><!-- end item fc011566-40d9-4bba-81bd-74870bb856ba -->","subChapters":[]}]},{"id":"a632a34d-e7e2-58cd-879a-6d6dc9405033","slug":"managing-eye-problems","fullItemName":"Managing eye problems","depth":4,"htmlHeader":"<!-- begin field 89f947dd-cb62-4b3e-a1a7-0a0c81b1b18b --><h4>How should I manage eye problems in a person with sickle cell disease?</h4><!-- end field 89f947dd-cb62-4b3e-a1a7-0a0c81b1b18b -->","summary":null,"htmlStringContent":"<!-- begin item 92923fe9-0f15-4a43-b231-24060d47e1fa --><!-- begin field 0c773e49-25f7-4a6f-b64c-44ee1599cd7b --><p><strong>All people with sickle cell disease should be evaluated yearly by an ophthalmologist. Ocular problems are rare before 15 years of age.</strong></p><ul><li><strong>Refer people immediately if they present with:</strong><ul><li><strong>Acute loss of vision</strong> — this may be due to occlusion of the central retinal artery, which should be treated by immediate blood transfusion.</li><li><strong>Acute change in vision</strong> — causes include vitreous haemorrhage and retinal detachment.</li></ul></li></ul><!-- end field 0c773e49-25f7-4a6f-b64c-44ee1599cd7b --><!-- end item 92923fe9-0f15-4a43-b231-24060d47e1fa -->","subChapters":[{"id":"89445b92-ac2c-55ec-bb59-ced75dfb332a","slug":"basis-for-recommendation-5c7","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field bee099cf-0d3b-44da-b5fb-6d55acb54ca8 --><h5>Basis for recommendation</h5><!-- end field bee099cf-0d3b-44da-b5fb-6d55acb54ca8 -->","summary":null,"htmlStringContent":"<!-- begin item 5c7447f6-1e09-4318-af4a-3636fa8806d6 --><!-- begin field 8c452199-6b5e-4c2a-8a44-6b06c1408a4f --><p>This recommendation is based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care </em>published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>], and in a review article on managing sickle cell disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Claster and Vichinsky, 2003</a>].</p><!-- end field 8c452199-6b5e-4c2a-8a44-6b06c1408a4f --><!-- end item 5c7447f6-1e09-4318-af4a-3636fa8806d6 -->","subChapters":[]}]},{"id":"715eeea2-6c0d-5832-b6a5-cea1f3559e4a","slug":"managing-gallstones","fullItemName":"Managing gallstones","depth":4,"htmlHeader":"<!-- begin field 316b4dc2-730c-4bbe-8414-e13fdf9f16e9 --><h4>How should I manage gallstones in a person with sickle cell disease? </h4><!-- end field 316b4dc2-730c-4bbe-8414-e13fdf9f16e9 -->","summary":null,"htmlStringContent":"<!-- begin item 14fff019-3fad-4ee2-a3cd-a14b8199a9ba --><!-- begin field 497bdcac-5b62-4dbe-8beb-3f73e5f5cedf --><p><strong>Gallstones are very common and ofter cause intermittent abdominal pain.</strong></p><ul><li><strong>For management information, </strong>see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gallstones/\">Gallstones</a>.</li><li><strong>If the gallstones are causing unbearable symptoms, </strong>refer the person for consideration of cholecystectomy.</li></ul><!-- end field 497bdcac-5b62-4dbe-8beb-3f73e5f5cedf --><!-- end item 14fff019-3fad-4ee2-a3cd-a14b8199a9ba -->","subChapters":[{"id":"3dd34854-7b9b-57c3-a6d7-25d7a8ad0ae7","slug":"basis-for-recommendation-a63","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 9c4bcc01-69cf-4335-b0ff-e052fc949871 --><h5>Basis for recommendation</h5><!-- end field 9c4bcc01-69cf-4335-b0ff-e052fc949871 -->","summary":null,"htmlStringContent":"<!-- begin item a63c09df-464d-4a96-b1e6-8e7605addfd4 --><!-- begin field 2f768095-59c6-4eb2-a21a-6505733e5cfb --><p>This recommendation is based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</p><!-- end field 2f768095-59c6-4eb2-a21a-6505733e5cfb --><!-- end item a63c09df-464d-4a96-b1e6-8e7605addfd4 -->","subChapters":[]}]},{"id":"aa8de257-0a00-5ae1-8acd-b7df78557432","slug":"managing-impaired-growth","fullItemName":"Managing impaired growth","depth":4,"htmlHeader":"<!-- begin field eb08306e-619a-4796-8d1a-bb181298eec3 --><h4>How should I manage impaired growth in a child or young person with sickle cell disease?</h4><!-- end field eb08306e-619a-4796-8d1a-bb181298eec3 -->","summary":null,"htmlStringContent":"<!-- begin item e7e26564-6020-49e5-b8a6-2beb55d7bfc4 --><!-- begin field 9a6c77e9-4a4e-4607-af34-62fc69be091e --><p><strong>Growth (weight and height) will usually be monitored at least annually in secondary care.</strong></p><ul><li><strong>Consider:</strong><ul><li>Zinc supplementation if growth is retarded (seek specialist advice).</li><li>Referral to a paediatric dietitian if the child is hospitalized frequently.</li><li>Referral to a paediatric endocrinologist if there are no physical signs of puberty by 14 years of age in a girl, and by 14 years 6 months of age in a boy.</li></ul></li><li><strong>Reassure children with delayed growth and delayed puberty (and/or their parents/carers) that they will reach a normal adult height.</strong></li></ul><!-- end field 9a6c77e9-4a4e-4607-af34-62fc69be091e --><!-- end item e7e26564-6020-49e5-b8a6-2beb55d7bfc4 -->","subChapters":[{"id":"95a99c3d-1f52-5715-8b75-552b9ff0222c","slug":"basis-for-recommendation-7a6","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field a0f9853a-c6db-4d4e-8032-7e03704438ff --><h5>Basis for recommendation</h5><!-- end field a0f9853a-c6db-4d4e-8032-7e03704438ff -->","summary":null,"htmlStringContent":"<!-- begin item 7a63060c-f3e1-4a9d-9971-f75dd7e2e614 --><!-- begin field eeb1a875-dc07-4389-a29c-78a6b22a2aec --><p>These recommendations are largely based on recommendations in the guideline <em>Sickle cell disease in childhood: standards and guidelines for clinical care </em>published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>].</p><h6>Considering zinc supplementation</h6><ul><li>The guideline development group (GDG) of the joint guideline identified evidence from a randomized controlled trial (RCT) which showed some improvement in height and weight after supplementation with zinc sulphate. Another controlled trial showed a reduction in infections and hospital admissions in children taking zinc supplements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>]. Based on these, the GDG concluded that zinc supplementation should be considered if growth is retarded. </li><li>A Cochrane systematic review (search date: February 2013) assessed the effect of zinc supplementation in the treatment of thalassaemia and sickle cell disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Swe et al, 2013</a>].<ul><li>There was no evidence from RCTs to indicate any benefit of zinc supplementation with regards to serum zinc level in people with thalassaemia. However, height velocity was noted to increase among those who received zinc supplements.</li></ul></li></ul><h6>Delay in puberty</h6><ul><li>Expert opinion in the joint guideline is that puberty may be delayed by 2–3 years in children with sickle cell disease, and by 6 months in children with Hb SC sickle cell disorder. However, delayed skeletal maturation during adolescence allows for a longer growth period in the long bones; therefore, children and their parents can be reassured that the child will attain a normal adult height [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>].</li></ul><!-- end field eeb1a875-dc07-4389-a29c-78a6b22a2aec --><!-- end item 7a63060c-f3e1-4a9d-9971-f75dd7e2e614 -->","subChapters":[]}]},{"id":"a340a87f-1662-59d4-9003-db5ecba5693b","slug":"managing-leg-ulcers","fullItemName":"Managing leg ulcers","depth":4,"htmlHeader":"<!-- begin field f02e0dc8-9c76-416d-8f5f-65f8d88811f4 --><h4>How should I manage leg ulcers in a person with sickle cell disease?</h4><!-- end field f02e0dc8-9c76-416d-8f5f-65f8d88811f4 -->","summary":null,"htmlStringContent":"<!-- begin item 9f5edb00-9cda-4a8e-b49c-e075c0984319 --><!-- begin field bbdc9fb1-631f-43de-afc3-fc7c6e0c72a9 --><p><strong>Leg ulcers will often be managed in secondary care by a multidisciplinary team, according to local guidelines. </strong></p><ul><li><strong>The primary healthcare professional should:</strong><ul><li><strong>Prescribe adequate pain relief.</strong> See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> for more information on pain relief.</li><li><strong>Suspect underlying osteomyelitis </strong><hyperlink-marker innertext=\"osteomyelitis\" refid=\"-476098\"></hyperlink-marker><strong>if the person has:</strong><ul><li>Fever.</li><li>Bone tenderness.</li><li>A high leukocyte count.</li><li>A high C-reactive protein level.</li></ul></li><li><strong>Seek specialist advice if</strong> the ulcer fails to respond to conservative measures. </li></ul></li></ul><!-- end field bbdc9fb1-631f-43de-afc3-fc7c6e0c72a9 --><!-- end item 9f5edb00-9cda-4a8e-b49c-e075c0984319 -->","subChapters":[{"id":"fe1bfabe-b394-57b2-bfde-a44157b0f803","slug":"basis-for-recommendation-c50","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 70ff153d-d4d7-4d4e-a898-840652ff05f5 --><h5>Basis for recommendation</h5><!-- end field 70ff153d-d4d7-4d4e-a898-840652ff05f5 -->","summary":null,"htmlStringContent":"<!-- begin item c505c8e9-36af-46d7-9df7-0119aad4df7e --><!-- begin field 3e1e5eef-cb5e-4d64-9af1-36df4f9189da --><p>These recommendations are largely based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>]<em> </em>and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</p><!-- end field 3e1e5eef-cb5e-4d64-9af1-36df4f9189da --><!-- end item c505c8e9-36af-46d7-9df7-0119aad4df7e -->","subChapters":[]}]},{"id":"1396f234-c4eb-5c8d-962f-ec08154751b5","slug":"managing-episodes-of-priapism","fullItemName":"Managing episodes of priapism","depth":4,"htmlHeader":"<!-- begin field 4eb05bf5-b1e6-4f1e-b846-8ba718d24457 --><h4>How should I manage episodes of priapism in a person with sickle cell disease?</h4><!-- end field 4eb05bf5-b1e6-4f1e-b846-8ba718d24457 -->","summary":null,"htmlStringContent":"<!-- begin item 3b2bd80e-c7ac-414d-bb45-58ef1768dcf0 --><!-- begin field 0bc94a9a-c1fd-4098-8426-3af18a99fea8 --><p><strong>Priapism is common and can be an acute or chronic complication of sickle cell disease. It is important to enquire about this issue as the person may be too embarrassed to report it.</strong></p><ul><li><strong>Minor episodes of priapism may be treated in primary care provided that the episodes:</strong><ul><li>Are isolated or infrequent.</li><li>Last less than 3 hours.</li></ul></li><li><strong>Advise the following to help abort an attack:</strong><ul><li>Bladder emptying before sleep.</li><li>Jogging.</li><li>Warm baths.</li><li>Analgesia.</li></ul></li><li><strong>Advise the man that if priapism persists,</strong> he should attend hospital and allow enough time so that emergency hospital treatment can be started within 3 hours.</li><li><strong>Refer</strong> <strong>men with stuttering priapism</strong> (frequent minor attacks several times a week) to a specialist, as oral etilefrine may be beneficial.</li></ul><!-- end field 0bc94a9a-c1fd-4098-8426-3af18a99fea8 --><!-- end item 3b2bd80e-c7ac-414d-bb45-58ef1768dcf0 -->","subChapters":[{"id":"ad9860fa-606d-5630-a142-f301de719bbe","slug":"basis-for-recommendation-d79","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field c5b2f89b-44b3-4e3b-b1e5-51175849f46f --><h5>Basis for recommendation</h5><!-- end field c5b2f89b-44b3-4e3b-b1e5-51175849f46f -->","summary":null,"htmlStringContent":"<!-- begin item d79218a4-9c22-4d0b-b853-00532f79625b --><!-- begin field d2c61790-c718-489a-bade-bff7a40e09de --><p>These recommendations are largely based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</p><h6>Priapism as a medical emergency</h6><ul><li>The time that is required to elapse before priapism is considered to be a medical emergency differs slightly between guideline groups:<ul><li>Expert opinion in the guideline <em>Sickle cell disease in childhood: standards and guidelines for clinical care </em>is that acute priapism becomes an emergency after 3 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>].</li><li>Expert opinion in the guideline <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>is that acute priapism becomes an emergency after 4 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</li></ul></li><li>Due to the risk of cavernosal fibrosis and impotence, which are serious and potentially permanent consequences of prolonged, untreated priapism, CKS recommends that the shorter time of 3 hours should be considered a medical emergency.</li></ul><!-- end field d2c61790-c718-489a-bade-bff7a40e09de --><!-- end item d79218a4-9c22-4d0b-b853-00532f79625b -->","subChapters":[]}]},{"id":"1193a13f-a5ae-5277-a83c-c33e0f924593","slug":"managing-nocturnal-enuresis","fullItemName":"Managing nocturnal enuresis","depth":4,"htmlHeader":"<!-- begin field 936db54a-2604-4dfa-a146-7d5bf9a91197 --><h4>How should I manage nocturnal enuresis in a child with sickle cell disease?</h4><!-- end field 936db54a-2604-4dfa-a146-7d5bf9a91197 -->","summary":null,"htmlStringContent":"<!-- begin item e3bb41de-8a62-484b-9d5b-a65cb5901551 --><!-- begin field 598e29fc-7bd7-4e61-9d11-a1be82152c26 --><p><strong>Nocturnal enuresis will often be managed in secondary care. However, the primary care clinician will need to provide supportive care and advice.</strong></p><ul><li><strong>Explain</strong> to the child and/or the parents/carers that enuresis is common in people with sickle cell disease, because they produce large quantities of dilute urine.</li><li><strong>Give general advice on the management of enuresis. </strong>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/bedwetting-enuresis/\">Bedwetting (enuresis)</a> for more information.<ul><li>Be aware that children with sickle cell disease tend not to respond to behavioural management techniques, such as star charts and mattress alarms.</li></ul></li><li><strong>Consider treatment with</strong> <strong>oral or nasal desmopressin, </strong>particularly for school trips or sleepovers.</li><li><strong>Refer children:</strong><ul><li>To an ear, nose, and throat specialist if the history is suggestive of obstructive sleep apnoea, as hypoxia may exacerbate nocturnal enuresis.</li><li>A specialist enuresis clinic if the child is still enuretic by 7 years of age.</li></ul></li></ul><!-- end field 598e29fc-7bd7-4e61-9d11-a1be82152c26 --><!-- end item e3bb41de-8a62-484b-9d5b-a65cb5901551 -->","subChapters":[{"id":"b2339b04-dd27-54f1-80ee-dcdd9830c9f4","slug":"basis-for-recommendation-f0c","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field ce241f7c-2a01-4bb9-add8-da50aafa4604 --><h5>Basis for recommendation</h5><!-- end field ce241f7c-2a01-4bb9-add8-da50aafa4604 -->","summary":null,"htmlStringContent":"<!-- begin item f0ca97e0-16fa-41c5-8a12-b5a19ff12deb --><!-- begin field f96ebfa3-7acc-488e-9989-28fe785ec322 --><p>These recommendations are based on expert opinion in the guideline <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and in a British Medical Journal (BMJ) review article on sickle cell anaemia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Brousse et al, 2014</a>].</p><!-- end field f96ebfa3-7acc-488e-9989-28fe785ec322 --><!-- end item f0ca97e0-16fa-41c5-8a12-b5a19ff12deb -->","subChapters":[]}]},{"id":"a1626739-373a-5c54-9312-da261e408d15","slug":"managing-pulmonary-hypertension","fullItemName":"Managing pulmonary hypertension","depth":4,"htmlHeader":"<!-- begin field 8d190bf4-7d66-4fc5-b9a4-29fec07ae77e --><h4>How should I manage pulmonary hypertension in a person with sickle cell disease?</h4><!-- end field 8d190bf4-7d66-4fc5-b9a4-29fec07ae77e -->","summary":null,"htmlStringContent":"<!-- begin item d8b9b79d-9bd2-4e3f-abfd-2e80bb8e2c6f --><!-- begin field affe48b9-1ba9-48cd-884a-cd5d61732659 --><p><strong>People with pulmonary hypertension will be managed in secondary care. Pulmonary hypertension is often asymptomatic (even when severe). Adults with sickle cell disease should be screened every 1–2 years using transthoracic echocardiography; children will be screened if they have chronic sickle lung or unexplained hypoxia.</strong></p><ul><li><strong>Refer children and adults urgently if they develop symptoms of pulmonary hypertension, including:</strong><ul><li>Worsening hypoxia.</li><li>Chest pain.</li><li>Increasing breathlessness.</li></ul></li></ul><!-- end field affe48b9-1ba9-48cd-884a-cd5d61732659 --><!-- end item d8b9b79d-9bd2-4e3f-abfd-2e80bb8e2c6f -->","subChapters":[{"id":"4085ff42-7519-5a97-a80a-178611e12687","slug":"basis-for-recommendation-f8a","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 13926f13-2c77-4864-92b3-c4e511bc23c0 --><h5>Basis for recommendation</h5><!-- end field 13926f13-2c77-4864-92b3-c4e511bc23c0 -->","summary":null,"htmlStringContent":"<!-- begin item f8af1b1a-6316-422f-b784-7b055e9682f3 --><!-- begin field 6e2c1410-40a4-4a5a-adbc-f15ae3bcccb7 --><p>This recommendation is based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care </em>published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>]<em> </em>and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>], and on expert opinion in a review article on managing sickle cell disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Claster and Vichinsky, 2003</a>].</p><!-- end field 6e2c1410-40a4-4a5a-adbc-f15ae3bcccb7 --><!-- end item f8af1b1a-6316-422f-b784-7b055e9682f3 -->","subChapters":[]}]},{"id":"1ed2d687-41a9-5717-b6f0-7408418361e3","slug":"managing-renal-disease-hypertension","fullItemName":"Managing renal disease and hypertension","depth":4,"htmlHeader":"<!-- begin field efc0b284-9b70-47d9-9b30-578dac0e4275 --><h4>How should I manage renal disease and hypertension in a person with sickle cell disease? </h4><!-- end field efc0b284-9b70-47d9-9b30-578dac0e4275 -->","summary":null,"htmlStringContent":"<!-- begin item d5a4aea5-940f-476e-9345-b7ab6c190c4a --><!-- begin field 273f2044-42e6-4ea9-aef1-142dd71097aa --><p><strong>Blood pressure, urea and electrolytes, and dipstick testing of the urine for protein will be done annually from childhood in secondary care. Primary care clinicians will be involved in monitoring for hypertension and chronic kidney disease (CKD).</strong></p><ul><li><strong>Aim for a target blood pressure of:</strong><ul><li>130/80 mmHg in people who have proteinuria.</li><li>140/90 mmHg in people with no proteinuria.</li></ul></li><li><strong>Advise a good fluid intake to prevent dehydration, </strong>as people with sickle cell disease produce large quantities of dilute urine.</li><li><strong>Be aware that renal function may deteriorate rapidly in people with sickle cell disease. </strong><ul><li><strong>Refer the following to a renal physician for further investigations:</strong><ul><li>All people with new hypertension or newly increased urea or creatinine levels.</li><li>All people with new proteinuria (quantified by measuring an albumin–creatinine ratio, a protein–creatinine ratio, or the amount of protein in a 24-hour urine collection), as this may be associated with a rapid decline in renal function. Treatment with an angiotensin-converting enzyme inhibitor or an angiotensin-II receptor antagonist is protective.</li></ul></li></ul></li><li><strong>Refer children and adults with haematuria.</strong></li><li><strong>Refer children and adults urgently if they present with symptoms suggestive of </strong><strong>renal medullary cancer </strong><strong>— haematuria, weight loss, loin pain, fever, and abdominal pain.</strong><ul><li>Refer using the suspected cancer pathway referral (for an appointment within 2 weeks).</li></ul></li></ul><!-- end field 273f2044-42e6-4ea9-aef1-142dd71097aa --><!-- end item d5a4aea5-940f-476e-9345-b7ab6c190c4a -->","subChapters":[{"id":"80487266-2b58-5d2a-8392-835f03d65136","slug":"basis-for-recommendation-50e","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 9e3bf359-f94b-4212-a99c-5ccfdfb90ba6 --><h5>Basis for recommendation</h5><!-- end field 9e3bf359-f94b-4212-a99c-5ccfdfb90ba6 -->","summary":null,"htmlStringContent":"<!-- begin item 50ef23fd-6cb0-4717-b827-3934a793a3d8 --><!-- begin field 6e506749-be10-49eb-9b02-fcf3607ba7da --><h6>Blood pressure and renal monitoring</h6><ul><li><p>These recommendations are based on expert opinion in the guidelines <em>Sickle cell disease in childhood: standards and guidelines for clinical care</em> published by the NHS Sickle Cell and Thalassaemia Screening Programme in partnership with the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">PHE, 2010</a>] and <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</p></li></ul><h6>Haematuria</h6><ul><li>The recommendation that all people with haematuria should be investigated is based on expert opinion in a review article on managing sickle cell disease, which states that in people with sickle cell disease, haematuria may occur secondary to papillary necrosis or, very rarely, be due to renal medullary carcinoma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Claster and Vichinsky, 2003</a>].</li><li>The clinical features of renal medullary cancer are based on expert opinion in the <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>].</li></ul><!-- end field 6e506749-be10-49eb-9b02-fcf3607ba7da --><!-- end item 50ef23fd-6cb0-4717-b827-3934a793a3d8 -->","subChapters":[]}]},{"id":"f7a0e73c-d613-58b9-a934-74d43ccb75a8","slug":"managing-sleep-apnoea","fullItemName":"Managing sleep apnoea","depth":4,"htmlHeader":"<!-- begin field 1aa25415-4ee6-4601-bbe8-bf6a34ace77e --><h4>How should I manage sleep apnoea in a person with sickle cell disease?</h4><!-- end field 1aa25415-4ee6-4601-bbe8-bf6a34ace77e -->","summary":null,"htmlStringContent":"<!-- begin item b1bbbedb-b848-4eac-b7ad-d2fc2d20dc99 --><!-- begin field 39706e1c-346f-4082-b4d4-e135a1f49a40 --><p><strong>Sleep apnoea is common in children and adults with sickle cell disease and may be due to tonsillar hypertrophy or other causes of sleep disordered breathing.  </strong></p><ul><li>Refer<strong> </strong>children and adults with a history suggestive of sleep apnoea for sleep studies.</li></ul><!-- end field 39706e1c-346f-4082-b4d4-e135a1f49a40 --><!-- end item b1bbbedb-b848-4eac-b7ad-d2fc2d20dc99 -->","subChapters":[{"id":"53bb5ca3-71ce-5640-a224-245eb4f955a9","slug":"basis-for-recommendation-81e","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 1db13a79-9846-449a-90ab-0abf2f726194 --><h5>Basis for recommendation</h5><!-- end field 1db13a79-9846-449a-90ab-0abf2f726194 -->","summary":null,"htmlStringContent":"<!-- begin item 81e73254-d5cb-4ddc-a268-47f44b2367e9 --><!-- begin field 13050f46-55f7-43e3-a829-33485fa93867 --><p>This recommendation is based on expert opinion in the guideline <em>Standards for the clinical care of adults with sickle cell disease in the UK </em>published by the Sickle Cell Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/sickle-cell-disease/references/\">Sickle Cell Society, 2008</a>], which states that it is important to diagnose and treat any underlying cause of sleep apnoea, as hypoxia can lead to an increase in the number of acute painful episodes and strokes.</p><!-- end field 13050f46-55f7-43e3-a829-33485fa93867 --><!-- end item 81e73254-d5cb-4ddc-a268-47f44b2367e9 -->","subChapters":[]}]}]}]}}},"staticQueryHashes":["3666801979"]}